• <acronym id="lfotb"><blockquote id="lfotb"></blockquote></acronym>

      <optgroup id="lfotb"></optgroup>

      1. <optgroup id="lfotb"><li id="lfotb"><source id="lfotb"></source></li></optgroup><optgroup id="lfotb"><i id="lfotb"></i></optgroup>

        1. <legend id="lfotb"></legend>

          <legend id="lfotb"></legend>
          <span id="lfotb"><output id="lfotb"><b id="lfotb"></b></output></span>
          <span id="lfotb"><sup id="lfotb"></sup></span>
            <track id="lfotb"></track>
            <acronym id="lfotb"><sup id="lfotb"></sup></acronym>
            <span id="lfotb"></span>

            > „>˾ӑB

            ̩IgAIڔIKW

            05

            2021.11

            rg11510c30̩IgAIRо2021IKWԺʽչRԇMչKLate-Breaking Clinical Trial@ɘsаlȫׂpcίϵyԼtǯˎٴµmY@Gȫ


            IKWAmerican Society of NephrologyASNǚvʷƾõćH피IKWMһһȵIKܴASN Kidney WeekȫҎģWgˮƽߵIKWgʢ֮һ˴ASN̩բRоɱWһtԺIȿƏΠ^ur̩IgAIίеЧԺͰȫ@ʾˎ24̩ܺ240mgMԇ򵰰ˮƽc@24Сr򵰰ƽˮƽ^½49%ڰοMнyӋWxp<0.05̩՜p˸LUIgAIߵĵ܉ЧIgAIMչLUҰȫ


            IgAIIgA NephropathyIgANҊԭlIСI֮һ҇sռԭlIС򼲲25%- 50% 25%-30% 20ȕlչɽKĩI(ESRD)˹ɳĵYAӋȫIgAI߿2030_1020f҇240f


            ָֹfȱJᘌίȫПo@ίIgAIЧˎĿǰĘ˜ʯI-ѪܾoأȩͪϵyăίƄƤ|صᘌLUȺMһίĿǰδȥ²ֻЇصĶRؽᘌIgAIȰȫЧί


            ǰЇH̩һNԭˎ̎RоAӢRԇȫ׿ͬׄBLyS/APRILpcںϵׄˎ̩ͨ^YBlyscAPRILɂӰBͻԵҪBİlͿwɞIgAIίx_Ƅί•rǰԓˎIgAImYѫ@ˎO֣FDAĢRԇM


            39̩ի@ÇˎƷO־҇ίϵyԼtǯˎаlIǰFشͻϵyԼtǯԓˎ߀НNо޴δMRmYίIgAICҕ񽛼lӲYذYomYćȢ/Rԇȫչ_жmYȫRоS̩ίõ@FڶN߼ϵRrֵõC


            һ һ

            ٷ΢

            ©  ŲWվ䰸̖ICP11031710̖-1
            91ƷƵ,Ʒ¶Ƶۿ,Ʒһ,99ȾžֻоƷ10,ȾþþƷ